Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
Background
Cited by
Items 201–300 of 409
Approaches for dosage individualisation in critically ill patients
de Gatta, M. A. D. M. F., Martín‐Suárez, A., & Lanao, J. M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.822486 · Cited by 15
“Because the interstitial space is the target site for most bacterial infections, this issue may be of clinical relevance for hydrophilic antimicrobial agents [13,17,18].”
BackgroundAardema, H., Bult, W., van Hateren, K., Dieperink, W., Touw, D. J., Alffenaar, J. C., & Zijlstra, J. G. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz463 · Cited by 15
In vitro Evaluation of Linezolid and Doripenem Clearance with Different Hemofilters
Hiraiwa, T., Moriyama, K., Matsumoto, K., Shimomura, Y., Kato, Y., Yamashita, C., Hara, Y., Kawaji, T., Kurimoto, Y., Nakamura, T., et al. (2020) · Blood Purification · doi:10.1159/000504039 · Cited by 14
Lee, D. H., Kim, H.-S., Park, S., Kim, H. I., Lee, S., & Kim, Y.-K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111861 · Cited by 14
“The “third spacing” phenomenon caused by vasodilation and capillary leakage in sepsis patients increases the volume of distribution and lowers the drugs’ serum concentration, especially for hydrophilic antimicrobials [1,2], such as β-lactams and aminoglycoside, that are more affected by pathophysiological changes than…”
BackgroundCorcione, S., D’Avolio, A., Loia, R. C., Pensa, A., Segala, F. V., Nicolò, A. D., Fatiguso, G., Romeo, M., Perri, G. D., Stella, M., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.06.011 · Cited by 13
Kumta, N., Heffernan, A. J., Cotta, M. O., Wallis, S. C., Livermore, A., Starr, T., Wong, W. T., Joynt, G. M., Lipman, J., & Roberts, J. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00142-22 · Cited by 13
“Optimizing antibiotic dosing to maximize antibiotic exposures at the infection site (cerebrospinal fluid [CSF]) is an important strategy that may improve therapeutic outcomes in critically ill patients (2, 3).”
BackgroundDomes, C., Popp, J., Hagel, S., Pletz, M. W., & Frosch, T. (2023) · The Analyst · doi:10.1039/d3an00402c · Cited by 13
Current treatment of community-acquired pneumonia
Liapikou, A., & Torres, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.798647 · Cited by 13
“The most studied antibiotics in PK/PD studies are ceftazidime in CAP [22] and meropenem, piperacillin/tazobactam ceftazidime in critical ill patients [23].”
BackgroundAbdul-Aziz, M. H., Rahman, A. N. A., Nor, M. B. M., Sulaiman, H., Wallis, S. C., Lipman, J., Roberts, J. A., & Staatz, C. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01543-15 · Cited by 13
Cies, J. J., LaCoursiere, R. J., Moore, W. S., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.6.467 · Cited by 13
Optimised Dosing of Vancomycin in Critically Ill Indigenous Australian Patients with Severe Sepsis
Tsai, D., Stewart, P., Hewagama, S. S., Krishnaswamy, S., Wallis, S. C., Lipman, J., & Roberts, J. A. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600405 · Cited by 13
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment
Gorham, J., Taccone, F. S., & Hites, M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2056012 · Cited by 13
“their clinical conditions, drug PK frequently varies during therapy with the risk of either treatment failure or toxicity [2,3].”
BackgroundImproved Treatment of Multidrug-Resistant Bacterial Infections: Utility of Clinical Studies
Bettiol, E., Rottier, W. C., del Toro, M. D., Harbarth, S., Bonten, M. J. M., Rodríguez‐Baño, J., & on behalf of the COMBACTE consortium (2014) · Future Microbiology · doi:10.2217/fmb.14.35 · Cited by 13
Personalised beta-lactam therapy: basic principles and practical approach
Streit, F., Perl, T., Schulze, M. H., & Binder, L. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0050 · Cited by 12
Laporte-Amargós, J., Gudiol, C., Arnán, M., Puerta‐Alcalde, P., Carmona-Torre, F., Huguet, M., Albasanz‐Puig, A., Parody, R., García‐Vidal, C., del Pozo, J. L., et al. (2020) · Trials · doi:10.1186/s13063-020-04323-0 · Cited by 12
Barreto, E. F., Rule, A. D., Al‐Shaer, M. H., Roberts, J. A., Abdul-Aziz, M. H., Scheetz, M. H., Mara, K. C., Jannetto, P. J., Gajic, O., O’Horo, J. C., et al. (2021) · Implementation Science Communications · doi:10.1186/s43058-021-00134-9 · Cited by 12
“Substantial inter- [7, 8] and intra-patient [9] variability in betalactam concentrations have been observed in critically ill patients which is thought to contribute to suboptimal effectiveness, safety, and development of antibiotic resistance [10].”
BackgroundBhalodi, A. A., Keel, R. A., Quintiliani, R., Lodise, T. P., Nicolau, D. P., & Kuti, J. L. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r789 · Cited by 12
“4 We attribute the slightly lower Cl in our population to the underlying renal function of the populations; the median (range) CrCl of patients included in our study was lower (76 [15-221] mL/min vs 97.”
BackgroundSulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Craig, W. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu055 · Cited by 13
“quired for tissue penetration in patients with shock or hypotension [5].”
Multidisciplinary guidelines on renal replacement therapy in intensive care medicine
Meersch, M., Abu-Tair, M., Bayer, M., Brinkmann, A., Bellmann, R., Brunkhorst, F., Custodis, F., Czock, D., Frey, O. R., Galle, J. N., et al. (2026) · Critical Care · doi:10.1186/s13054-025-05817-6 · Cited by 13
Subtherapeutic piperacillin concentrations in neurocritical patients
Damen, C., Dhaese, S. A. M., Verstraete, A., Stove, V. V., & Waele, J. J. D. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.07.007 · Cited by 12
Yang, Y., Wang, Y., Zeng, W., Zhou, J., Xu, M., Lan, Y. W., Liu, L., Shen, J., Zhang, C., & He, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-64223-0 · Cited by 12
“Many studies have shown that the plasma drug concentration of water-soluble antibiotics decreases in patients with severe infection 12 , and the dose should be increased appropriately.”
Vooren, S. V., Waele, J. J. D., Boelens, J., Polet, M., Stove, V. V., Vanhaecke, L., & Verstraete, A. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338760 · Cited by 11
Real-life use of ceftobiprole for severe infections in a French intensive care unit
Bellut, H., Arrayago, M., Amara, M., Roujansky, A., Micaëlo, M., Bruneel, F., & Bédos, J. (2023) · Infectious Diseases Now · doi:10.1016/j.idnow.2023.104790 · Cited by 11
An MEKC assay for the therapeutic drug monitoring of cefepime
Theurillat, R., Sendi, P., & Thormann, W. (2013) · Journal of Separation Science · doi:10.1002/jssc.201300402 · Cited by 11
Dahdouh, E., Shoucair, S., Salem, S. E., & Daoud, Z. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/979648 · Cited by 11
Valero, A., Rodríguez‐Gascón, A., Isla, A., Barrasa, H., del Barrio-Tofiño, E., Oliver, A., Canut, A., & Solinís, M. Á. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111899 · Cited by 11
Significant publications on infectious diseases pharmacotherapy in 2014
Phe, K., Cadle, R. M., Guervil, D. J., Guzmán, O. E., Lockwood, A. M., Perez, K. K., Vuong, N. N., & Aitken, S. L. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150112 · Cited by 11
Drug Dosing in Critically Ill Patients with Acute Kidney Injury and on Renal Replacement Therapy
Rao, N. S. (2015) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23392 · Cited by 10
Chen, C., Seabury, R. W., Steele, J. M., Parsels, K. A., Darko, W., Miller, C. D., & Kufel, W. D. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac117 · Cited by 10
How should we dose antibiotics for pneumonia in the ICU?
Udy, A. A., Roberts, J. A., & Lipman, J. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835d19e0 · Cited by 11
Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients
Chung, E. K., Fleming, M. R., Cheatham, S. C., & Kays, M. B. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016676831 · Cited by 10
“Changes in renal function, development of sepsis with capillary leak syndrome, use of vasopressors, and administration of large volumes of resuscitation fluids in critically ill patients may result in increased or decreased CL of renally eliminated drugs and increased volume for hydrophilic drugs, such as doripenem.(1…”
BackgroundThe role of mass spectrometry in antibiotic stewardship
Zander, J., Paal, M., & Vogeser, M. (2018) · Clinical mass spectrometry · doi:10.1016/j.clinms.2018.11.001 · Cited by 10
Hassanpour, R., Ziaie, S., Kobarfard, F., Kouchek, M., Miri, M. M., Koomleh, A. A., Shojaei, S., Salarian, S., Pourheidar, E., Nezarat, F., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03062-0 · Cited by 10
Willam, C., Abu-Tair, M., Bayer, M., Bellmann, R., Brunkhorst, F. M., Custodis, F., Galle, J. C., Hermes, C., Joannidis, M., John, S., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01293-6 · Cited by 9
Treatment of KPC-2 Enterobacter cloacae empyema with cefepime and levofloxacin
Cardile, A. P., Briggs, H. L., Burguete, S., Herrera, M., Wickes, B. L., & Jorgensen, J. H. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.10.012 · Cited by 9
“Beta-lactam therapy can be pharmacodynamically optimized via increasing the percentage of time that serum antibiotic concentration exceeds the MIC (%T N MIC) with extended or continuous infusion regimens (Gonçalves-Pereira and Póvoa, 2011).”
BackgroundČižmárová, I., Mikuš, P., Švidrnoch, M., & Piešťanský, J. (2024) · Pharmaceuticals · doi:10.3390/ph17040526 · Cited by 9
“Some studies demonstrated that the optimal bactericidal activity is also attained when the plasma concentrations of ATBs exceed four to five times the MIC for 70% to 100% of the dosing interval [11–14].”
BackgroundBaptista, J. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_7 · Cited by 10
Iyer, R. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00212-7 · Cited by 21
Is continuous infusion of imipenem always the best choice?
Suchánková, H., Lipš, M., Urbánek, K., Neely, M. N., & Strojil, J. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.005 · Cited by 10
Cheng, V., Rawlins, M. D. M., Chang, T., Fox, E., Dyer, J. R., Allen, C., Litton, E., Page, M. M., Hoad, K., & Roberts, J. A. (2019) · Chemotherapy · doi:10.1159/000499375 · Cited by 9
Gewebepenetration von Antibiotika: Erreicht die Behandlung den Zielort?
Lagler, H., & Zeitlinger, M. A. (2014) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0309-0 · Cited by 11
Luque, S., Benítez-Cano, A., Larrañaga, L., Sorlí, L., Navarrete-Rouco, M. E., Campillo, N., Carazo, J., Ramos, I., Adàlia, R., & Grau, S. (2021) · Antibiotics · doi:10.3390/antibiotics10060666 · Cited by 10
“makes meropenem a common choice for the treatment of severe infections in critically ill patients [1,2].”
BackgroundPiperacillin/tazobactam treatment in children: evidence of subtherapeutic concentrations
Ye, P., Shi, J., Guo, Z., Yang, X., Li, Q., Chen, K., Zhao, F., Zhou, H., Zhang, Y., van den Anker, J. N., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1254005 · Cited by 8
First dose target attainment with extended infusion regimens of piperacillin and meropenem
Beijer, G., Swartling, M., Nielsen, E. I., Breuer, O., Giske, C. G., Eliasson, E., & Petersson, J. (2025) · Critical Care · doi:10.1186/s13054-025-05445-0 · Cited by 10
“An important reason for this is the altered pharmacokinetics associated with critical illness [9, 11].”
Bédos, J., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., Guery, B. P., Joram, N., et al. (2014) · Réanimation · doi:10.1007/s13546-014-0916-7 · Cited by 11
Assawatheptawee, K., Kiddee, A., Na-udom, A., Wangteeraprasert, A., Treebupachatsakul, P., & Niumsup, P. R. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.10.017 · Cited by 8
Kwong, A. C., O’Jeanson, A., & Khier, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00681-5 · Cited by 8
“Notably, the pharmacokinetics of β-lactam antibiotics are heterogeneous and largely unpredictable in patients admitted to intensive care units (ICU) and TDM of β-lactam antibiotics such as carbapenems is highly recommended [3, 4].”
BackgroundCeftazidime-avibactam for the treatment of complicated intra-abdominal infections
Buckman, S. A., Krekel, T., Muller, A. E., & Mazuski, J. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1249847 · Cited by 9
“Beta-lactam pharmacokinetics in ICU patients is quite heterogeneous due to changes in volume of distribution as well as clearance [54].”
Quickfall, D., La, A. M., Pisano, J. C., Costello, P., Gunning, S., & Koyner, J. L. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04272-3 · Cited by 8
“Some literature supports CRRT itself as an independent risk factor for MDRO colonization or infection, likely mediated through prolonged antibiotic exposure, catheter use, and biofilm formation [32–37].”
de Cacqueray, N., Boujaafar, S., Bille, E., Moulin, F., Gana, I., Benaboud, S., Hirt, D., Béranger, A., Toubiana, J., Renolleau, S., et al. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000918 · Cited by 7
Lejbman, I. A., Torisson, G., Resman, F., & Sjövall, F. (2024) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14382 · Cited by 7
“14”
Gonçalves-Pereira, J., Fernandes, J., Mendes, T. F., Gonzalez, F. A., & Fernandes, S. M. (2024) · Antibiotics · doi:10.3390/antibiotics13090853 · Cited by 8
“Nevertheless, a clear relationship between antibiotic tissue concentration and outcomes is lacking [27].”
BackgroundSelf-citationPitarch, E. E., Gumucio-Sanguino, V. D., Sacristán, S. C., Shaw, E., Maisterra-Santos, K., Sabater‐Riera, J., Pérez-Fernández, X. L., Rigo-Bonnin, R. F., Tubau, F., Carratalà, J., et al. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00694-0 · Cited by 7
Martínez-Casanova, J., Pitarch, E. E., Colom, H., Gumucio-Sanguino, V. D., Sacristán, S. C., Shaw, E., Maisterra-Santos, K., Sabater‐Riera, J., Pérez-Fernández, X. L., Rigo-Bonnin, R. F., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030531 · Cited by 9
Pharmacokinetic considerations for drugs administered in the critically ill
Tansley, G., & Hall, R. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.2.89 · Cited by 7
“…is proportional to clearance and inversely proportional to half-life (t1/2β), an increased volume of distribution may increase the amount of time an antibiotic is above the minimum inhibitory concentration, resulting in an equivalent or even improved efficacy (Gonçalves-Pereira and Póvoa, 2011).”
BackgroundContinuous β-Lactam Infusion to Optimize Antibiotic Use for Severe Sepsis. A Knife Cutting Water?
Chastre, J. E., & Luyt, C. E. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1487ed · Cited by 8
Koedijk, J. B., Valk-Swinkels, C. G. H., Rijpstra, T. A., Touw, D. J., Mulder, P. G. H., van der Voort, P. H. J., Veer, N. E. V. ‘., & van der Meer, N. J. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02888-15 · Cited by 7
“The extracorporeal clearance is especially relevant for drugs with a dominant renal clearance and results in unpredictable pharmacokinetics (8).”
BackgroundAminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients
Grucz, T. M., Kruer, R. M., Bernice, F., Lipsett, P. A., Dorman, T., Sugrue, D., & Jarrell, A. S. (2020) · Surgical Infections · doi:10.1089/sur.2020.012 · Cited by 7
“In these patients, the V d is increased because of factors such as large-volume fluid resuscitation, infusion of blood products, third spacing, vasopressor use, surgery, and positive-pressure ventilation [6,7].”
Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets
Al‐Shaer, M. H., & Peloquin, C. A. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.02.020 · Cited by 7
Weinelt, F. A., Stegemann, M. S., Theloe, A., Pfäfflin, F., Achterberg, S., Weber, F., Dübel, L., Mikołajewska, A., Uhrig, A., Kießling, P., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11060758 · Cited by 10
“Especially in critically ill patients, pathophysiological changes can lead to altered PK and exposure of antibiotic drugs [9].”
BackgroundLiebchen, U., Klose, M., Paal, M., Vogeser, M., Zöller, M., Schroeder, I., Schmitt, L., Huisinga, W., Michelet, R., Zander, J., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10040468 · Cited by 7
“The time during which the unbound meropenem concentration remains above the minimal inhibitory concentration (fT > MIC) has been related to therapeutic success [7,18].”
BackgroundHe, X., Liu, X., Gong, X., Wang, L., & Chen, F. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230325121729 · Cited by 6
Tebano, G., la Martire, G., Raumer, L., Cricca, M., Melandri, D., Pea, F., & Cristini, F. (2023) · Antibiotics · doi:10.3390/antibiotics12121737 · Cited by 8
“Beta-lactams have a wide therapeutic window, with high concentration thresholds for toxicity [21], and this approach has already been suggested for the overall population of critically ill patients [52,53,55–57].”
BackgroundMethodTherapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
You, X., Dai, Q., Hu, J. Y., Yu, M., Wang, X., Weng, B., Cheng, L., & Sun, F. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.01.004 · Cited by 8
Nielsen, M. B. D., Jørgensen, A. R., Stilling, M., Mikkelsen, M. K. D., Jørgensen, N. P., & Bue, M. (2024) · Apmis · doi:10.1111/apm.13490 · Cited by 6
Tilanus, A., Shields, R. K., Lodise, T. P., & Drusano, G. L. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf038 · Cited by 7
Liao, J., Li, C., & Li, L. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2465427 · Cited by 6
“Consequently, it is widely utilized in the treatment of severe hospital-acquired infections in inpatient settings [1,2].”
Zavřelová, A., Šíma, M., Maláková, J., Rozsívalová, P., Paterová, P., Žák, P., Víšek, B., Michaličková, D., Slanař, O., & Radocha, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15612 · Cited by 7
Population Pharmacokinetic Study of Benzylpenicillin in Critically Unwell Adults
Shah, R. V., Kipper, K., Baker, E. H., Barker, C. I. S., Oldfield, I., Philips, B. J., Johnston, A. E., Lipman, J., Rhodes, A., Basarab, M., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12040643 · Cited by 7
Comparison of the influence on renal function between cefepime and cefpirome
Jiang, M., YAO, J., ZHANG, L., GAO, T., ZHANG, Y., WENG, X., & Feng, G. (2015) · Biomedical Reports · doi:10.3892/br.2015.528 · Cited by 6
Pharmacotherapy for hospital-acquired pneumonia
Liapikou, A., Rosales-Mayor, E., & Torres, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.889115 · Cited by 7
Monitorización terapéutica de antibióticos: Nuevas metodologías: biosensores
Soto, D., Silva, C. S., Andresen, M., Soto, N., Wong, K., & Andresen, M. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000800013 · Cited by 6
Antibiotics and extracorporeal circulation – one size does not fit all
Gonçalves-Pereira, J., & Oliveira, B. (2014) · Critical Care · doi:10.1186/s13054-014-0695-6 · Cited by 6
“in PK, especially the increased volume of distribution and clearance variation [7], secondary to volume resuscitation, increased cardiac output and capillary leak.”
BackgroundSelf-citationMa, Y., Zhou, Y., Huang, J., Qin, H., Wang, P., & Wu, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.01.017 · Cited by 6
Varela-Rey, I., Martínez-Guitián, M., Hermelo-Vidal, G., Bandín‐Vilar, E., Novo‐Veleiro, I., Varela-García, P. M., Zarra‐Ferro, I., González‐Barcia, M., Mondelo‐García, C., & Fernández‐Ferreiro, A. (2025) · Antibiotics · doi:10.3390/antibiotics14060613 · Cited by 5
Zeng, J., Leng, B., Guan, X., Jiang, S., Xie, M., Zhu, W., Tang, Y., Zhang, L., Sha, J., Wang, T., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347130 · Cited by 5
Antimicrobial Dosing during Extracorporeal Membrane Oxygenation
Honoré, P. M., Jacobs, R., & Spapen, H. D. (2014) · Springer eBooks · doi:10.1007/978-3-319-03746-2_4 · Cited by 5
Tse, A., Ling, L., Joynt, G. M., & Lee, A. S. Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.028 · Cited by 6
Meropenem serum concentrations in intensive care patients: a retrospective analysis
Ďuricová, J., Kacířová, I., & Brozmanová, H. (2020) · Česká a slovenská farmacie · doi:10.36290/csf.2020.032 · Cited by 5
Kavi, J., Bhattacharjee, D., Macve, J. C., & Weinbren, M. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks378 · Cited by 5
Extended Infusion of Broad-spectrum β-Lactams in High-risk Febrile Neutropenic Patients
Gudiol, C., Laporte, J., Albasanz‐Puig, A., Sánchez‐Ortega, I., Cuervo, G., & Carratalà, J. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy783 · Cited by 5
Závorszky, L., Rádler, A., Galgóczi, J., Tóth, B. G., Csomós, Á., Erőss, A., Farkas, R., Karvaly, G., Holub, L., Szabó, B. G., et al. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32896 · Cited by 4
Totschnig, D., Mader, T., Stimpfl, T., Breinbauer, K., Groza, C., Stücklschwaiger, D., Neuhold, S., Friese, E., Holbik, J., Delivuk, M., et al. (2025) · Infection · doi:10.1007/s15010-025-02554-4 · Cited by 4
“The efficacy of beta-lactam antibiotics depends on maintaining drug concentrations above the path-ogen's minimum inhibitory concentration (fT > MIC) [5].”
Correia, P. A., Launay, M., Balluet, R., Gergelé, L., Gauthier, V., Morel, J., Beuret, P., Mariat, C., Thiéry, G., & Périnel, S. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad339 · Cited by 7
Reeder, J. A., Creech, C. B., Nation, R. L., Gu, K., Nalbant, D., Wu, N., Jimenez‐Truque, N., Fissell, W. H., Rolsma, S. L., Fishbane, N., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6161 · Cited by 5
Horstink, M. M. B., Geel, D. R., den Uil, C. A., Deetman, P. E., Endeman, H., Abdulla, A., Bosch, T. M., Rietdijk, W. J. R., Thielen, F. W. F., Haringman, J. J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10747-3 · Cited by 4
(SRLF), S. D. R. D. L. F., (Sfar), S. F. D.-R., & Bretonnière, C. (2015) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2015.06.001 · Cited by 5
Pharmacological considerations of antibiotic failures in bovine respiratory disease cases
Lubbers, B. V. (2020) · Animal Health Research Reviews · doi:10.1017/s1466252320000122 · Cited by 4
“…be increased by some of the pathophysiologic changes that occur as a result of systemic disease, while other factors may decrease the concentrations of antimicrobials; thus making the sum effects on pharmacokinetics ‘markedly unpredictable’ for these patients (Goncalves-Pereira and Povoa, 2011).”
BackgroundYe, L., Cheng, L., Kong, L., Zhao, X., Xie, G., He, J. N., Liu, H., Deng, Y., Wu, X., Wang, T., et al. (2022) · Analytical Methods · doi:10.1039/d1ay01385h · Cited by 4
Systematic Review and Meta-Analysis of the Effect of Loop Diuretics on Antibiotic Pharmacokinetics
Kerling, D. A., Clarke, S., DeLuca, J. P., Evans, M. O., Kress, A. T., Nadeau, R. J., & Selig, D. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051411 · Cited by 4
Ishikawa, K., Shibutani, K., Kawai, F., Ota, E., Takahashi, O., & Mori, N. (2023) · Antibiotics · doi:10.3390/antibiotics12061024 · Cited by 5
Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
Gan, Y., Meng, X., Lei, N., Yu, H. B., Zeng, Q., & Huang, Q. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s408572 · Cited by 5
Cies, J. J., Moore, W. S., Conley, S. B., SHEA, P. A., Enache, A., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.1.69 · Cited by 4
Optimizing Antibiotic Administration for Pneumonia
Motos, A., Kidd, J. M., & Nicolau, D. P. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.08.006 · Cited by 6
König, C., Kluge, S., Fuhrmann, V., & Jarczak, D. (2021) · The International Journal of Artificial Organs · doi:10.1177/03913988211021101 · Cited by 4
Acute Kidney Injury and Renal Replacement Therapy
Choi, G. Y. S., & Joynt, G. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_6 · Cited by 4
Chen, L., Qu, X., Su, J., Yao, H., Yuan, Q., Wang, Y., Li, N., Wu, G., Liu, X., Hu, J., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1183332 · Cited by 3
“The antibiotic pharmacokinetics in critically ill patients may perform differently; for example, the half-life (T1/2) and % T>MIC of the hydrophilic β-lactam antibiotics in critically ill patients were unpredictable (Gonçalves-Pereira and Póvoa, 2011), and the exposure of 1.”
BackgroundCharoenwong, K., Wacharachaisurapol, N., Sukkummee, W., Sophonphan, J., Suchartlikitwong, P., Chatsuwan, T., Anugulruengkitt, S., & Puthanakit, T. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004582 · Cited by 3
Kumta, N., Heffernan, A. J., Liu, X., Parker, S. L., Cotta, M. O., Wallis, S. C., Livermore, A., Starr, T., Wai, W. T., Joynt, G. M., et al. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107461 · Cited by 4
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.